Healthy populations require affordable access to health products, especially vaccines that prevent illness. To address access gaps, global health stakeholders work to cultivate what we call “healthy markets,” ensuring that manufacturers invest in the production of quality products at affordable prices suitable for people everywhere, including in lower- and middle-income countries (LMICs). Market shaping—the practice of supporting healthy markets—in turn requires accurate, up-to-date data on vaccine supply, vaccine demand, prices, and more.
Historically, vaccine market data was siloed and messy. Intelligence on important suppliers, such as developing country vaccine manufacturers (DCVMs), was unreliable. Beginning in 2015, Linksbridge collaborated with key global health partners to develop a data platform that would power market health interventions.
Data as a global public good
Built from continuously updated public and private information from the Bill & Melinda Gates Foundation, CHAI, Gavi, PAHO, PATH, UNICEF, U.S. CDC, WHO, and other sources, today’s GVMM provides high-quality, comprehensive intelligence reviewed and refined by Linksbridge’s in-house data scientists and market experts. The platform includes:
- Demand module – featuring Linksbridge demand forecasts (through 2040) for existing products, forecasted vaccine introductions, and forecasted product replacements
- Products and supply module – drawing on confidential donor investment data and supplier-validated intelligence, this module includes development pipelines, marketed products, WHO prequalified products, supplier capacity, time to market, and probability of technical and regulatory success (PTRS) discount
- Pricing – Reference data from 2020–present and Linksbridge pricing model forecasts through 2040 for tiers including USA, super HICs, HICs, UMICs, China, other LMICs, India, PAHO, UNICEF, and more
- Market share, market value, and more – Linksbridge estimates of overall market value, global and Gavi market volumes and revenues, segmented country demand, franchise value, and additional analytics based on counterpart needs
Outcomes
GVMM data informs market-shaping interventions like those that have helped reduce the cost of pentavalent, pneumococcal, and rotavirus vaccines by nearly a third over the past decade. Accurate, timely data and reliable forecasts help stakeholders from the country level to the global level understand markets, anticipate pricing, supply, and other access challenges, and develop solutions.
Ongoing GVMM access for global health counterparts is made possible by a 2023 grant from the Gates Foundation. To request access, please use this form.
